

FORM PTO-1390  
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

US471

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/744605

INTERNATIONAL APPLICATION NO.  
PCT/FR99/01901INTERNATIONAL FILING DATE  
30 July 1999PRIORITY DATE CLAIMED  
31 July 1998

## TITLE OF INVENTION

Use of Novel Agents Inducing Cell Death in Synergy with Interferons

## APPLICANT(S) FOR DO/EO/US

KOKEN, M.; QUIGNON, F.; DE THE, H.; AMEISEN, J.C.; DE BELS, F.


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:  
 Certificate of Mailing by Express Mail  
 Post Card  
 Express Mailing Label No.: EL065516252US  
 Deposited 26 January 2001

09/744605

S. APPLICATION NO. (37 CFR 1.5)		INTERNATIONAL APPLICATION NO. PCT/FR99/01901		ATTORNEY'S DOCKET NUMBER US471	
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. .... \$1000.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00 <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>  \$ 860.00 \$ 130.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	11 - 20 =	0	x \$18.00	\$ 0.00	
Independent claims	7 - 3 =	4	x \$80.00	\$ 320.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 270.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1580.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 0.00 +	
<b>SUBTOTAL =</b>				\$	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	
<b>TOTAL NATIONAL FEE =</b>				\$ 1580.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ 0.00	
<b>TOTAL FEES ENCLOSED =</b>				\$ 1580.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>501365</u> in the amount of \$ <u>1580.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>501365</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card</b> <b>information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO: Butler, Gregory B. Serono Reproductive Biology Institute 280 Pond Street Randolph, MA 02368 United States of America					
				SIGNATURE  Gregory B. Butler	
				NAME 34,558	
				REGISTRATION NUMBER	

7/PPB

09/744605  
500 Rec'd PCT/PTO 26 JAN 2001

WO 00/07616

PCT/FR99/01901

Use of novel agents inducing cell death in synergy with  
interferons

The present invention relates to the use of  
5 novel agents inducing cell death, and in particular of  
an agent allowing the overexpression of the PML protein  
on nuclear bodies, in combination with interferons, to  
induce the death of undesirable cells.

Nuclear bodies are structures associated with  
10 the nuclear matrix, of unknown function, and which  
contain a number of proteins including PML, Sp100,  
ISG20, PIC-1/SUMO-1, Iyap100, PLZF, Int-6, CBP, Rb, RFP  
and the ribosomal P protein (Lamond et al., 1998). The  
gene encoding the PML (for "ProMyelocytic Leukemia")  
15 protein was identified from its fusion with the RAR $\alpha$   
(retinoic acid nuclear receptor) gene in the t(15;17)  
translocation found in patients suffering from acute  
promyelocytic leukaemia (APL). This PML gene is a  
target gene for interferons, and its overexpression  
20 causes stoppage of the growth of certain cell lines  
(Koken et al., 1995). In malignant APL cells, the PML  
protein is not located on the nuclear body but  
delocalized because of the expression of PML-RAR $\alpha$ .  
Arsenic oxide induces the return of PML to its normal  
25 location as well as the death of the cell. In normal  
non-APL cells, where the location of PML is normal,  
arsenic induces the aggregation of PML towards large  
modified bodies, but the phenomenon is not accompanied  
by cell death (Zhu et al., 1997).

30 The authors of the invention have now  
discovered that the overexpression of the PML protein  
located on the nuclear bodies causes the death of the  
cell through a novel mechanism different from that of  
apoptosis induced by caspases.

35 The major consequence of this discovery is that  
a substance promoting the targeting of the PML protein  
to the cellular bodies and/or its stabilization is

particularly useful for inducing the death of undesirable cells.

5 The said substances which induce the targeting of the PML protein to the nuclear bodies and/or its stabilization may be identified by standard tests known to a person skilled in the art, it being possible for the measurement of the intracellular transit between the cytoplasmic and nucleoplasmic fractions and the fraction associated with the nuclear bodies and the  
10 stabilization of the PML protein to be carried out in particular by Western blotting.

The said undesirable cells may be in particular cells of a tumour, cells infected with a virus, a parasite or a bacteria, immune cells participating in  
15 an inappropriate immune reaction, genetically modified cells, senescent or hyperplasic cells.

The expression "tumour" is understood to mean any undesirable, benign or malignant cell proliferation including in particular solid cancers and leukaemias  
20 and lymphomas. Among the malignant tumours, there may be mentioned in particular chronic myeloid leukaemias and adult T lymphoid leukaemias (ATL) and melanomas.

The subject of the present invention is therefore the use of at least one substance promoting  
25 the targeting of the PML protein towards the nuclear bodies and/or its stabilization, for the production of a medicament intended to induce the death of undesirable cells.

The expression of the PML protein being induced  
30 by interferons, the presence of interferons, whether of endogenous origin or administered to the patient simultaneously or sequentially, is necessary for the efficacy of the treatment envisaged.

Surprisingly, the authors of the present  
35 invention have more particularly discovered that zVAD (benzyloxycarbonyl-Val-Ala-Asp(O - methyl) fluoromethyl ketone), on the one hand, stabilizes the PML protein

and, on the other hand, accelerates cell death induced by the interferons.

However, zVAD is initially known as an inhibitor of caspases, which are proteases involved in the apoptosis process (Salvesen et al., 1997). Studies (McCarthy et al., 1997) have in addition shown that zVAD prevented or greatly delayed cell death. The discovery by the authors of the present invention, according to which zVAD does not block cell death induced by the interferons but, on the contrary, accelerates it, is therefore in disagreement with the results which could be expected by persons skilled in the art.

The subject of the present invention is more particularly the use of a caspase inhibitor and/or substrate, such as zVAD, for the production of a medicament intended to induce the death of undesirable cells. The acceleration of cell death which is observed may be a consequence of the stabilization of PML but may also involve other mechanisms, which remain within the framework of the present invention.

The expression "caspase substrate" is understood to mean any compound capable of binding to caspases.

The authors of the present invention have also discovered that arsenic, and more particularly arsenic trioxide, on the one hand, promotes the targeting of the PML protein towards cellular bodies and, on the other hand, accelerates cell death induced by interferons.

The subject of the present invention is more particularly the use of a compound of arsenic or of a compound having the same biological properties as arsenic, for the production of a medicament intended to induce the death of undesirable cells, in association with at least one interferon.

This induction of cell death which is observed may be a consequence of the targeting of the PML

protein towards the cellular bodies, but may also involve other mechanisms, which remain within the framework of the present invention.

Among the compounds of arsenic, there may be mentioned in particular arsenic trioxide or melarsoprol.

The expression "compound having the same biological properties as arsenic" is understood to mean any compound which, like arsenic, is an inhibitor of phosphatase and/or is capable of creating covalent adducts by binding with dithiol groups.

The caspase inhibitors and/or substrates or the compounds of arsenic or the compounds having the same biological properties as arsenic are preferably used to induce the death of the undesirable cells, in association with the PML protein, and/or with an agent inducing the overexpression of the PML protein. Among the agents inducing the overexpression of the PML protein, an interferon, such as  $\alpha$ -,  $\beta$ - or  $\gamma$ -interferon, is preferably used.

Indeed, the authors of the present invention have more particularly discovered that the caspase substrates, in particular zVAD, as well as the compounds of arsenic, in particular arsenic trioxide, acted in synergy with the interferons to induce and accelerate cell death.

The simultaneous or sequential administration of PML or of an agent inducing the overexpression of the PML protein, such as the interferons, may be unnecessary if the quantity of PML or of agent inducing the overexpression of the PML protein, such as the interferons, of endogenous origin, is sufficient. Nevertheless, according to a preferred embodiment of the invention, the administration of a substance chosen from the compounds of arsenic, the compounds having the same biological properties as arsenic and the caspase inhibitors and/or substrates, is associated with a simultaneous or sequential administration of PML

protein, and/or of an agent inducing the overexpression of the PML protein, such as the interferons.

Forming part of the invention is the use of a substance chosen from the compounds of arsenic, the  
5 compounds having the same biological properties as arsenic and the caspase inhibitors and/or substrates, in association with an interferon, to induce the death of undesirable cells, whether it is mediated by the PML protein induced by the said interferon or by another  
10 mechanism also induced by the said interferon.

The subject of the present invention is also a method of therapeutic treatment in which a therapeutically effective quantity of at least one substance chosen from the compounds of arsenic, the  
15 compounds having the same biological properties as arsenic and the caspase inhibitors and/or substrates are administered to a patient requiring such a treatment, in association with a pharmaceutically acceptable vehicle.

20 Preferably, a therapeutically effective quantity of PML protein, and/or of an agent inducing the overexpression of the PML protein, such as an interferon, is also administered to the said patient, simultaneously or sequentially.

25 The subject of the present invention is also a pharmaceutical composition containing

1) either at least one caspase inhibitor and/or substrate combined with:

- at least one compound of arsenic or one  
30 compound having the same biological properties as arsenic;

- and/or the PML protein

- and/or at least one agent inducing the overexpression of the PML protein, such as an  
35 interferon;

in the presence of a pharmaceutically acceptable vehicle;

2) or at least one compound of arsenic or one compound having the same biological properties as arsenic, associated with the PML protein and/or with at least one agent inducing the overexpression of the PML  
5 protein, such as an interferon, in the presence of a pharmaceutically acceptable vehicle.

The subject of the present invention is also a kit comprising

a) - a pharmaceutical composition (1) containing at  
10 least one caspase inhibitor and/or substrate, in association with a pharmaceutically acceptable vehicle;

- and/or a pharmaceutical composition (2) containing at least one compound of arsenic or one compound having the same properties as arsenic, in  
15 association with a pharmaceutically acceptable vehicle; and

b) - a pharmaceutical composition (3) containing the PML protein in association with a pharmaceutically acceptable vehicle;

20 - and/or a pharmaceutical composition (4) containing at least one agent inducing the overexpression of the PML protein, such as an interferon, in association with a pharmaceutically acceptable vehicle;

25 the said pharmaceutical compositions being intended for simultaneous or sequential administration.

The mode of administration and the dosage depend on the condition treated and its state of progression, as well as the weight, age and sex of the  
30 patient.

In accordance with the invention, the formulation of the medicaments of the invention allows administration in particular by the oral, anal, nasal, intramuscular, intradermal, subcutaneous or intravenous  
35 route.

The dose for administration envisaged may be for example from 1 to 50 mg per day, preferably by the intravenous route, for the compounds of arsenic, from 1



to 250 mg per kg of body weight of caspase substrates such as zVAD, and from 1 to 20 millions of international units (M IU), preferably from 3 to 5 M IU, preferably by the intramuscular or subcutaneous route, per day or every two days, for interferon.

The authors of the invention have, in addition, discovered that the cell death induced by the overexpression of the PML protein located on the nuclear bodies has different characteristics from the apoptosis induced by caspases. In the case of the cell death induced by PML, the nuclear morphological characteristics typical of apoptosis, such as condensation of chromatin and nuclear fragmentation, are in particular not observed.

Furthermore, whereas the cell death induced by the interferons alone exhibits the characteristics of apoptosis, the authors of the present invention observed that the synergistic association of zVAD with the interferons causes this apoptotic phenotype to disappear, the cell death then exhibiting characteristics different from those of apoptosis.

One of the major consequences of this discovery is the capacity of the undesirable cells killed by the mechanism induced by PML to cause an immune reaction against similar undesirable cells which would have escaped death mediated by the PML protein.

This property makes particularly advantageous the use of a substance chosen from the compounds of arsenic, the compounds having the same biological properties as arsenic, and the caspase inhibitors and/or substrates, preferably in combination with an interferon, to induce the death of undesirable cells, and/or to induce an immune reaction.

Thus, the administration of these medicaments will allow a form of immunotherapy, or of "vaccination", by causing a reaction of the immune system which removes the surviving undesirable cells, whether they are cancer cells, infected cells or any

other undesirable cell which participates in the development of a disease.

5 This property is linked to the fact that these medicaments, in particular the association interferon and zVAD or zVAD alone, cause in the undesirable cells a phenomenon of death which does not possess all the characteristics of apoptosis, which is the most frequent physiological phenotype in cellular suicide.

10 In particular, the caspase inhibitor zVAD prevents the appearance of most of the manifestations of apoptosis, which depend on an activation, in the dying cell, of certain caspases. Indeed, while the caspases are not essential for the execution of cellular suicide, they appear, on the other hand, to be  
15 essential during the phenomena of cellular suicide, for the execution of an apoptotic death phenotype (Xiang J. et al., PNAS 1996, 93: 14559; Quignon F. et al., Nature Genetics 1998, 20: 259; Vercammen D. et al., J. Exp. Med. 1998, 187: 1477).

20 A number of results suggest that the manner in which a cell dies plays an important role in the induction or otherwise of an immune reaction directed against the surviving cells possessing the same characteristics (including for example the nature of  
25 the abnormality which makes them cancerous, or the nature of the infectious agent which they contain).

The onset, in a cell, of a phenomenon of apoptotic death would have the effect of limiting the induction of an immune reaction against the surviving  
30 cells possessing the same characteristics, or even of promoting the induction of a form of immune tolerance, that is to say of a selective inhibition of the induction of an immune response directed against the surviving cells possessing the same characteristics.  
35 Results obtained in some particular models (in vitro or in vivo in the mouse eye anterior chamber), suggest that the apoptotic death of a cell could, in general, limit or inhibit the induction of delayed

hypersensitivity type cell-mediated immune reactions (termed Th1) mediated by the CD4+ T lymphocytes (Griffith T. et al., Immunity 1996, 5: 7; Voll R. et al., Nature 1997, 390: 350; Gao Y. et al., J. Exp. Med. 5 1998, 188: 887), a reaction which represents one of the essential manifestations of an effective immune reaction against undesirable cells.

In a particular model of tumours in mice, it has been shown that the onset, in cancer cells, of 10 phenomena of apoptotic death does not bring about the induction of an effective immune reaction directed against the live cancer cells exhibiting the same characteristics, whereas the artificial introduction into these cancer cells of a gene which prevents the 15 onset, in the dying cancer cells, of part of the apoptotic phenotype, allows the induction of an effective immune reaction directed against the live cancer cells exhibiting the same characteristics but into which this gene has not been artificially 20 introduced (Melcher et al., 1998, Nature Med., vol. 4, No. 5, pp 581-587).

The discovery that the medicaments described in this application cause the death of undesirable cells while not causing (or while preventing) the onset, in 25 the dying cells, of an apoptotic phenotype is therefore important. It implies that these medicaments would have the effect not only of causing the death of undesirable cells, but also of allowing the concomitant induction of an effective immune reaction allowing the 30 concomitant or subsequent elimination of the undesirable cells which would have escaped the death induced by the medicaments.

This property may also be exploited for treating ex vivo a combination of cells which are 35 likely to contain undesirable cells, before administration to a patient, for example a bone marrow preparation intended for a transplant in a leukaemia patient, such a preparation generally containing a few

residual malignant cells. Such a treatment not only makes it possible to induce the death of the undesirable cells contained in the preparation, but also to cause an immune reaction directed against the undesirable cells present in the body of the patient to whom the treated cell preparation is administered.

The subject of the present invention is therefore also an in vitro method for inducing the death of undesirable cells comprising bringing undesirable cells into contact with a substance chosen from the compounds of arsenic, the compounds having the same biological properties as arsenic, and the caspase inhibitors and/or substrates, it being possible for the said substance to be preferably associated with the PML protein and/or with an agent inducing the overexpression of the PML protein, preferably an interferon.

The following examples and figures illustrate the invention without limiting the scope thereof.

#### LEGEND TO THE FIGURES

- Figure 1A represents the induction of the PML protein of 90 kD in a clone REF(T)PML, four hours after exposure to variable concentrations of  $\text{ZnCl}_2$ .
- Figure 1B represents a FACS analysis of REF(T)PML cells or of control cells, four hours 30 minutes after exposure to 150  $\mu\text{M}$  of  $\text{ZnCl}_2$ . The left-hand panel represents the DNA content relative to the size of the cells. The right-hand panel represents the DNA content as a function of the fluorescence (TUNEL).
- Figure 1C represents the cytometric analysis of the REF(T)PML cells treated or otherwise with  $\text{ZnCl}_2$ , etoposide, or the caspase inhibitor zVAD. A labelling is carried out with Annexin V-FITC (left-hand panel) or Rhodamin 123 (right-hand panel). The percentage of apoptotic cells is indicated.
- Figure 2A represents the absence of cleavage of PARP during the cell death triggered by PML. The

cells were treated with 150  $\mu$ M ZnCl<sub>2</sub>, etoposide or zVAD.

5 - Figure 2B represents the activity of the caspase CPP32 determined by cleavage of DEVD-pNA in control REF(T) cells or REF(T)PML cells. Relative absorbance values for three independent determinations are presented.

10 - Figure 3A shows the survival of the monocytes treated with 1 000 U/ml of INF $\alpha$ . One representative experiment out of five is presented. The TUNEL tests demonstrate that the decrease in the cell count is due to apoptosis.

15 - Figure 3B represents histograms indicating the effect of zVAD (100  $\mu$ M) 24 hours after its addition. The mean values  $\pm$  standard deviation of 11 experiments are presented.

- Figure 4A shows that zVAD stabilizes the PML protein in the REF(T) cells.

20 - Figure 4B shows that  $\alpha$ -interferon (1 000 U/ml) induces rat PML in the REF(T)PML cells. The arrows indicate distinct isoforms of PML.

### EXAMPLES

#### MATERIALS AND METHODS

##### 25 - Plasmid construct

A SacI-BglIII fragment (- 69, + 55 base pairs) of the mouse metallothionein promoter was inserted into a plasmid pKS and was fused with a BglIII-BamHI fragment of a PML cDNA leading to the plasmid pKS<sub>MTT</sub>-PML. For the GFP-PML fusion, the same PML fragment was inserted into the BglIII site of the vector pEGFP-1 (Clontech). A retroviral vector expressing PML was also constructed by inserting a full-length cDNA for PML (de Thé et al., 1991) into the EcoRI site of SRatkneo (Muller et al., 35 1991).

##### - Cell culture

The REF(T) and MEF(T) cells are rat and mouse embryonic fibroblasts immortalized by an SV40T

expression vector. The REF(K1) cells are immortalized by an SV40T mutant which does not bind Rb, and the F111 cells are spontaneously immortalized 3T3 rat fibroblasts. For clonogenicity tests, the cells were  
5 transfected with 10  $\mu$ g of SRatkneo-PML or SRatkneo on culture dishes 10 cm in diameter and selected with neomycin (500  $\mu$ g/ml). To obtain inducible clones, a pool of REF(T) cells was cotransfected with the plasmid pKSmMt-PML and a hygromycin resistance vector (DSP-  
10 Hygro). The resistant colonies were examined for the expression of PML after four hours of treatment with  $\text{ZnCl}_2$  (150  $\mu$ M) and subjected to a second cycle of cloning by limiting dilution. Inducible CHO clones were constructed in a similar manner. The monocytes were  
15 prepared according to the method of Estaquier et al., 1997. Etoposide (used at 100  $\mu$ M for 16 to 24 hours) was obtained from Biomol Research Laboratories, zVAD (benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone, used at 250  $\mu$ g/ml) is marketed by Bachem and rat IFN $\alpha$   
20 by Access BioMedical. The human  $\alpha$ -interferon was provided by Schering-Plough. The antibodies against the human PML protein are described in the article by Daniel et al., 1993. The Western blot experiments with the endogenous rat PML protein were carried out with  
25 the monoclonal antibody 5E10 which detects both rat PML and human PML.

- Evaluation of cell death

The cells were treated for 2 hours with 150  $\mu$ M of  $\text{ZnCl}_2$  (unless otherwise stated) in the presence or  
30 absence of heat-inactivated foetal calf serum, and then the cells were washed and incubated in a  $\text{ZnCl}_2$ -free medium. The TUNEL test was carried out according to the manufacturer's instructions (Boehringer Mannheim, kit for detection of cell death in situ), with the  
35 exception of the fixing step (4% formaldehyde in phosphate PBS buffer for 10 minutes). The cellular DNA content was evaluated by incubating for 10 minutes in propidium iodide at 50  $\mu$ g/ml, in the presence of

Rnase A at 100 µg/ml at 4°C. Analysis of the expression of phosphatidylserine on the outer sheet of the cell membranes was carried out using Annexin-V-fluores labelling (Boehringer Mannheim) and a loss of  
5 mitochondrial polarity with Rhodamin 123 (molecular probes) according to the manufacturer's instructions. The samples were analysed on a FACScan analyser (Lysis II software, Becton Dickinson). For the cleavage of the substrate with caspases,  $5 \times 10^6$  cells were  
10 washed in PBS buffer, and incubated for one hour at 4°C in 200 µl of lysis buffer (10 mM Hepes, pH 7.4, 2 mM EDTA, 2 mM DTT, 0.1% CHAPS). After centrifugation, 20 µl of supernatant and 180 µl of reaction buffer (100 mM Hepes, pH 7.4, 2% of glycerol, 5 mM DTT, 0.5 mM  
15 EDTA, 50 µM DEVD-pNA (Biomol Research Laboratories)) were mixed and the absorbance at 405 nm was measured after incubating for four hours at 37°C. The anti-PARP polyclonal antibody SA-252 is marketed by Biomol Research Laboratories.

20

#### EXAMPLE 1

##### PML induces cell death independent of zVAD

The transfection of a PML expression vector (pSG5-PML) into various fibroblast cell lines  
25 substantially reduced the formation of foci. The PML protein being undetectable in the clones obtained from the cells transfected with PML, these results mean that PML exerts a major inhibitory effect either on the cell cycle or on the survival of the cells. To understand  
30 the mechanism which forms the basis of this effect, a pool of rat embryo fibroblasts (REFs) transformed with SV40T was transfected with a plasmid pKSmMT-PML, in which the expression of PML is under the control of a mouse metallothionein promoter. Three of the resulting  
35 REF(T)PML clones were subsequently studied, whereas three REF(T) clones carrying the empty vector were tested as control. The PML protein was detected by Western blotting two hours after exposure to  $ZnCl_2$

(expression detectable from 50  $\mu$ M of  $\text{ZnCl}_2$  and exhibiting a plateau at 150  $\mu$ M of  $\text{ZnCl}_2$ ) (Figure 1A). The expression of PML induced a synchronized cell death of the whole cell population with kinetics varying from 5 48 hours for 50  $\mu$ M of  $\text{ZnCl}_2$  to six hours for 150  $\mu$ M. In the three REF(T)PML clones, morphological modifications were observed from three hours after induction with 150  $\mu$ M of  $\text{ZnCl}_2$ . The cells round up, with clear shrinkage of the cytoplasm (Figure 1B), became positive 10 in a TUNEL test (Figure 1B) and then were progressively detached from the dish. They nevertheless retained their capacity to exclude trypan blue. These modifications were associated with a modest subG1 DNA content (Figure 1B), an externalization of membrane 15 phosphatidylserine (Figure 1C) and a loss of mitochondrial transmembrane potential (Figure 1C). While similar modifications were observed in apoptosis induced by the genotoxic agent etoposide, they were never found in the control REF(T) cells treated with 20  $\text{ZnCl}_2$  (Figures 1B and C). Unlike the treatment with etoposide, the cell death induced by PML is not associated with nuclear morphological characteristics typical of apoptosis such as condensation of chromatin and nuclear fragmentation, even late, in the process of 25 cell death. In spite of the cleavage of the DNA (positive sub-G1 (Figure 1B) and loss of the viscosity of the DNA), the cell death induced by PML is not associated with an internucleosomal DNA scale, in conformity with the weak positive TUNEL signal 30 (Figure 1B).

#### Controls:

As the REF(T) cells are cell lines transformed with SV40T, several experiments were carried out in order to exclude a contribution of the "large T" 35 oncogene of the SV40 virus to the cell death induced by PML. Firstly, the expression of PML did not adversely affect the expression or the location of SV40T in the REF(T)PML cells nor did it degrade p53 or the release



of p53 from the SV40 virus "large T" oncogene. Secondly, in the HeLa or CHO cells transiently transfected with either a fusion protein GFP-PML or GFP alone, all the GFP-PML positive cells gradually became detached from the dish and died, unlike the control GFP positive cells. Thirdly, in the CHO cells stably transfected with the plasmid pKSmMT-PML, the induction by  $\text{ZnCl}_2$  here again led to the death of the clones expressing the PML protein. Finally, in the REF cells expressing a heat-sensitive SV40T mutant, the degradation of the SV40Ts at  $39.5^\circ\text{C}$  did not affect the cell death triggered by PML.

The induction of cell death may require transcription *de novo* or may reflect the triggering of pre-existing pathways. The REF(T)PML cells were first of all incubated with  $\text{ZnCl}_2$  and with cycloheximide for two hours, thus allowing the synthesis of mRNA for PML, and not its translation. The cells were then washed and incubated with actinomycin D alone in order to allow the translation of the mRNA for PML but not the mRNA neosynthesis. In this experiment, cell death was observed as in the absence of inhibitor, showing that transcription *de novo* is not required. Death induced by PML does not require and does not induce transition towards the S phase of the cell cycle. Indeed, PML always triggers death in the REF(T)PML cells which have been blocked at the G1/S stage by a treatment with aphidicolin. Furthermore, exposure to BrdU at various times after induction with  $\text{ZnCl}_2$  showed that the replication of the DNA was not modified up to two hours but was stopped after three hours and that cell death was present in all the phases of the cell cycle (Figure 1B).

## 35 EXAMPLE 2:

### Arsenic promotes cell death triggered by PML

When the REF(T)PML cells were treated with  $\text{ZnCl}_2$  and  $10^{-6}$  M  $\text{As}_2\text{O}_3$ , a strong acceleration in the

morphological modifications associated with cell death was observed. The cleavage of the DNA, determined by TUNEL tests, increased in a similar manner (117% of positive cells for the cotreatment with  $\text{ZnCl}_2$  against 45% for  $\text{ZnCl}_2$  alone, whereas  $\text{As}_2\text{O}_3$  alone did not induce any increase relative to the basal level). The fact that arsenic increases the induction of cell death in parallel with the location of PML on the nuclear bodies suggests that the location of PML near the nuclear bodies is important for cell death.

### EXAMPLE 3:

Death triggered by PML is not associated with the activation of caspases

It is known that the execution of programmed cell death involves the proteolytic activation of caspases which induce the phenotypic changes in apoptosis by cleavage of nuclear and cytoplasmic proteins (Salvesen et al., 1997). The caspase inhibitor zVAD, which blocks apoptosis induced by etoposide, does not inhibit cell death induced by PML (Figure 1C) and even paradoxically accelerates it (71% of positive TUNEL signal with zVAD and  $\text{ZnCl}_2$  against 45% with  $\text{ZnCl}_2$  alone). These observations mean that executing agents sensitive to zVAD are not required for cell death induced by PML. Furthermore, CPP32 (caspase 3), the principal caspase involved in apoptosis, appears not to be activated during cell death induced by PML since one of its substrates, PARP (poly(ADP-ribose)polymerase) remains noncleaved (Figure 2A). Unlike etoposide, no significant cleavage of the colorimetric caspase substrates, YVAD-pNa (class 1 caspase, Boehringer Mannheim) and DEVD-pNA (class 3 caspase, Boehringer Mannheim) after induction with PML could be detected (Figure 2B).

**EXAMPLE 4:**

**Arsenic and zVAD potentiate cell death induced by PML and interferons**

Primary monocytes exposed to  $\alpha$ -interferon were subjected to gradual cell death which led to the complete disappearance of the cell culture after seven days (Figures 3A and 3B). During the addition of zVAD with  $\alpha$ -interferon, the death of the whole cell population was observed within 24 hours in the absence of nuclear fragmentation and of condensation of chromatin observed with interferon alone (Figures 3A and 3B). Little or no cell death was observed with zVAD alone for 20 days in most of the primary cultures (8/11) (Figures 3A and 3B). In three cultures out of eleven, zVAD alone induced the death of part of the culture after seven days, these results probably reflecting an endogenous secretion of interferon. Similar results were obtained with other caspase inhibitors such as DEVD.

The table below represents the cell death, evaluated by TUNEL, of REF(T)PML cells treated for two days with 1 000 U/ml of IFN $\alpha$  and  $10^{-6}$  M of As $_2$ O $_3$  or of zVAD.

	IFN $\alpha$	
	-	+
Control	5%	42%
zVAD	5%	60%
As $_2$ O $_3$	5.5%	63%

In the REF(T) cells, a substantial synergy was found between either  $\alpha$ -interferon and zVAD, or  $\alpha$ -interferon and As $_2$ O $_3$  (42% of positive TUNEL signal for  $\alpha$ -interferon alone, and 60% and 63% with zVAD and arsenic respectively).

zVAD increased the levels of expression of PML (Figure 4A) and arsenic increased its association with the nuclear bodies, whereas the total quantity of PML

was reduced. The similarity of the synergy of zVAD and arsenic with the cell deaths triggered by PML and interferon suggests that PML is involved with the cell death induced by interferon. Furthermore,  $\alpha$ -interferon  
5 induces cell death with the same kinetics as 50  $\mu$ M  $\text{ZnCl}_2$  and the two induced similar quantities of PML protein (Figure 4B).

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220

CLAIMS

1. Use of at least one substance:

5 - which promotes the targeting of the PML protein towards the nuclear bodies and/or its stabilization; and/or

10 - which is chosen from the compounds of arsenic, the compounds having the same biological properties as arsenic, and caspase inhibitors and/or substrates;

15 in combination with the PML protein and/or with an agent inducing the overexpression of the PML protein; for the manufacture of a medicament intended to induce the death of undesirable cells and/or stimulate an immune reaction, the administration of the said substance and the administration of the PML protein and/or of the said agent inducing the overexpression of the PML protein being simultaneous or sequential.

20 2. Use according to Claim 1, in which the said substance is arsenic trioxide.

3. Use according to Claim 1, in which the said substance is zVAD.

25 4. Use according to any one of Claims 1 to 3, in which the said agent inducing the overexpression of the PML protein is an interferon, such as  $\alpha$ -,  $\beta$ - or  $\gamma$ -interferon.

30 5. Use of at least one substance chosen from the compounds of arsenic, the compounds having the same biological properties as arsenic, and the caspase inhibitors and/or substrates, in association with an interferon, for the manufacture of a medicament intended to induce the death of undesirable cells and/or stimulate an immune reaction, the administration of the said substance and the administration of the interferon being simultaneous or sequential.

35 6. Method in vitro for inducing the death of undesirable cells comprising bringing undesirable cells into contact with a substance chosen from the compounds

of arsenic, the compounds having the same biological properties as arsenic, and the caspase inhibitors and/or substrates, the said substance being associated with the PML protein and/or with an agent inducing the overexpression of the PML protein, preferably an interferon.

7. Pharmaceutical composition containing

1) either at least one caspase inhibitor and/or substrate combined with:

- at least one compound of arsenic or one compound having the same biological properties as arsenic;

- and/or the PML protein

- and/or at least one agent inducing the overexpression of the PML protein, such as an interferon;

in the presence of a pharmaceutically acceptable vehicle;

2) or at least one compound of arsenic or one compound having the same biological properties as arsenic, associated with the PML protein and/or with at least one agent inducing the overexpression of the PML protein, such as an interferon, in the presence of a pharmaceutically acceptable vehicle.

8. Kit comprising

a) - a pharmaceutical composition (1) containing at least one caspase inhibitor and/or substrate, in association with a pharmaceutically acceptable vehicle;

- and/or a pharmaceutical composition (2)

containing at least one compound of arsenic or one compound having the same properties as arsenic, in association with a pharmaceutically acceptable vehicle; and

b) - a pharmaceutical composition (3) containing the PML protein in association with a pharmaceutically acceptable vehicle;

- and/or a pharmaceutical composition (4) containing at least one agent inducing the over-

expression of the PML protein, such as an interferon,  
in association with a pharmaceutically acceptable  
vehicle;

the said pharmaceutical compositions being intended for  
5 simultaneous or sequential administration.

9. Use of at least one substance, other than the  
compounds of arsenic, promoting the targeting of the  
PML protein towards the nuclear bodies and/or its  
stabilization, for the manufacture of a medicament  
10 intended to induce the death of undesirable cells,  
and/or stimulate an immune reaction.

10. Use of at least one substance chosen from  
caspase inhibitors and/or substrates for the  
manufacture of a medicament intended to induce the  
15 death of undesirable cells, and/or stimulate an immune  
reaction.

11. Use according to Claim 10, in which the said  
substance is zVAD.




FIG. 1A






FIG.1B




FIG. 1C





FIG.2A

FIG.2B




FIG.3A






FIG.3B

7/7



**FIG. 4A**



**FIG. 4B**

**APPLICATION FOR UNITED STATES LETTERS PATENT  
DECLARATION, POWER OF ATTORNEY, AND PETITION**

As a below named inventor, I declare that :

My residence, post office address and citizenship are as stated next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention which is described and which is claimed in the specification, entitled : Use of Novel Agents inducing Cell Death in Synergy with Interferons.

The specification ☐ is attached hereto  
☐ was filed on \_\_\_\_\_ as Application Serial Number \_\_\_\_\_  
☒ was filed as PCT International Application No PCT/FR99/01901  
on 30 July 1999

I hereby state that I have reviewed and understand the contents of said specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

COUNTRY	APPLICATION No	DATE (D/M/Y)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
France	FR 98/09886	31 July 1998	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL No	FILING DATE	STATUS


COMBINED DECLARATION AND POWER OF ATTORNEY

I hereby appoint my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the U.S. Patent & Trademark Office connected therewith:

Gregory Butler, Reg. No. 34,558.

CORRESPONDENCE AND CALLS TO : Gregory Butler  
Serono Reproductive Biology Institute  
280 Pond Street  
Randolph, MA 02368  
Telephone- (781) 681 27 96  
Fax - (781) 963 68 31

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S)	DATE	RESIDENCE & PO ADDRESS
Name : KOKEN Marcel Signature :	Date : Citizen of : The Netherlands	Appartement 116 15 allée Darius Milhaud F-75019 Paris France
Name : QUIGNON Frédérique Signature : 	Date : 31/03/2001 Citizen of : France	6, passage Charles Dallery F-75011 Paris France 54 rue du Dr Thore 92330 Sceaux
Name : DE THE Hugues Signature :	Date : Citizen of : France	146 rue de l'Université F-75007 Paris France
Name : AMEISEN Jean-Claude Signature :	Date : Citizen of : France	35 bis, rue Henri Barbusse F-75005 Paris France
Name : DE BELS Frédéric Signature :	Date : Citizen of : France	c/o M. Bilan 5, rue Frédéric Loliée F-75020 Paris France

FRX



**APPLICATION FOR UNITED STATES LETTERS PATENT  
DECLARATION, POWER OF ATTORNEY, AND PETITION**

As a below named inventor, I declare that :

My residence, post office address and citizenship are as stated next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention which is described and which is claimed in the specification, entitled : Use of Novel Agents inducing Cell Death in Synergy with Interferons.

The specification ☐ is attached hereto  
☐ was filed on \_\_\_\_\_ as Application Serial Number \_\_\_\_\_  
☒ was filed as PCT International Application No PCT/FR99/01901  
on 30 July 1999

I hereby state that I have reviewed and understand the contents of said specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

COUNTRY	APPLICATION No	DATE (D/M/Y)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
France	FR 98/09886	31 July 1998	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL No	FILING DATE	STATUS


COMBINED DECLARATION AND POWER OF ATTORNEY

I hereby appoint my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the U.S. Patent & Trademark Office connected therewith:

Gregory Butler, Reg. No. 34,558.

**CORRESPONDENCE AND CALLS TO :** Gregory Butler  
Serono Reproductive Biology Institute  
280 Pond Street  
Randolph, MA 02368  
Telephone- (781) 681 27 96  
Fax - (781) 963 68 31

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S)	DATE	RESIDENCE & PO ADDRESS
Name : KOKEN Marcel Signature :	Date : Citizen of : The Netherlands	Appartement 116 15 allée Darius Milhaud F-75019 Paris France
Name : QUIGNON Frédérique Signature :	Date : Citizen of : France	6, passage Charles Dallery F-75011 Paris France
Name : DE THE Hugues Signature : 	Date : 4/4/2001 Citizen of : France	146 rue de l'Université F-75007 Paris France
Name : AMEISEN Jean-Claude Signature :	Date : Citizen of : France	35 bis, rue Henri Barbusse F-75005 Paris France
Name : DE BELS Frédéric Signature :	Date : Citizen of : France	c/o M. Bilan 5, rue Frédéric Loliée F-75020 Paris France

**APPLICATION FOR UNITED STATES LETTERS PATENT  
DECLARATION, POWER OF ATTORNEY, AND PETITION**

As a below named inventor, I declare that :

My residence, post office address and citizenship are as stated next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention which is described and which is claimed in the specification, entitled : Use of Novel Agents inducing Cell Death in Synergy with Interferons.

The specification ☐ is attached hereto  
☐ was filed on \_\_\_\_\_ as Application Serial Number \_\_\_\_\_  
☒ was filed as PCT International Application No PCT/FR99/01901  
on 30 July 1999

I hereby state that I have reviewed and understand the contents of said specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

COUNTRY	APPLICATION No	DATE (D/M/Y)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
France	FR 98/09886	31 July 1998	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL No	FILING DATE	STATUS

COMBINED DECLARATION AND POWER OF ATTORNEY

61446

I hereby appoint my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the U.S. Patent & Trademark Office connected therewith:

Gregory Butler, Reg. No. 34,558.

CORRESPONDENCE AND CALLS TO :

Gregory Butler  
Serono Reproductive Biology Institute  
280 Pond Street  
Randolph, MA 02368  
Telephone- (781) 681 27 96  
Fax - (781) 963 68 31

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S)	DATE	RESIDENCE & PO ADDRESS
Name : KOKEN Marcel Signature :	Date : Citizen of : The Netherlands	Appartement 116 15 allée Darius Milhaud F-75019 Paris France
Name : QUIGNON Frédérique Signature :	Date : Citizen of : France	6, passage Charles Dallery F-75011 Paris France
Name : DE THE Hugues Signature :	Date : Citizen of : France	146 rue de l'Université F-75007 Paris France
Name : AMEISEN Jean-Claude Signature : <i>J. Ameyen</i>	Date : 9/05/2001 Citizen of : France	35 bis, rue Henri Barbusse F-75005 Paris France
Name : DE BELS Frédéric Signature :	Date : Citizen of : France	c/o M. Bilan 5, rue Frédéric Loliée F-75020 Paris France

**APPLICATION FOR UNITED STATES LETTERS PATENT  
DECLARATION, POWER OF ATTORNEY, AND PETITION**

As a below named inventor, I declare that :

My residence, post office address and citizenship are as stated next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention which is described and which is claimed in the specification, entitled : Use of Novel Agents inducing Cell Death in Synergy with Interferons.

The specification ☐ is attached hereto  
☐ was filed on \_\_\_\_\_ as Application Serial Number \_\_\_\_\_  
☒ was filed as PCT International Application No PCT/FR99/01901  
on 30 July 1999

I hereby state that I have reviewed and understand the contents of said specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

COUNTRY	APPLICATION No	DATE (D/M/Y)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
France	FR 98/09886	31 July 1998	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL No	FILING DATE	STATUS


COMBINED DECLARATION AND POWER OF ATTORNEY

I hereby appoint my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the U.S. Patent & Trademark Office connected therewith:

Gregory Butler, Reg. No. 34,558.

CORRESPONDENCE AND CALLS TO : Gregory Butler  
Serono Reproductive Biology Institute  
280 Pond Street  
Randolph, MA 02368  
Telephone- (781) 681 27 96  
Fax - (781) 963 68 31

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S)	DATE	RESIDENCE & PO ADDRESS
Name : KOKEN Marcel Signature :	Date : Citizen of : The Netherlands	Appartement 116 15 allée Darius Milhaud F-75019 Paris France
Name : QUIGNON Frédérique Signature :	Date : Citizen of : France	6, passage Charles Dallery F-75011 Paris France
Name : DE THE Hugues Signature :	Date : Citizen of : France	146 rue de l'Université F-75007 Paris France
Name : AMEISEN Jean-Claude Signature :	Date : Citizen of : France	35 bis, rue Henri Barbusse F-75005 Paris France
Name : DE BELS Frédéric Signature : 	Date : 26/03/2001 Citizen of : France	c/o M. Bilan 5, rue Frédéric Loliée F-75020 Paris France

**APPLICATION FOR UNITED STATES LETTERS PATENT  
DECLARATION, POWER OF ATTORNEY, AND PETITION**

As a below named inventor, I declare that :

My residence, post office address and citizenship are as stated next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the invention which is described and which is claimed in the specification, entitled : Use of Novel Agents inducing Cell Death in Synergy with Interferons.

The specification ☐ is attached hereto  
☐ was filed on \_\_\_\_\_ as Application Serial Number \_\_\_\_\_  
☒ was filed as PCT International Application No PCT/FR99/01901  
on 30 July 1999

I hereby state that I have reviewed and understand the contents of said specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

COUNTRY	APPLICATION No	DATE (D/M/Y)	PRIORITY CLAIMED UNDER 35 U.S.C. 119
France	FR 98/09886	31 July 1998	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL No	FILING DATE	STATUS

COMBINED DECLARATION AND POWER OF ATTORNEY

I hereby appoint my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the U.S. Patent & Trademark Office connected therewith:

Gregory Butler, Reg. No. 34,558.

CORRESPONDENCE AND CALLS TO : Gregory Butler  
Sero Reproductive Biology Institute  
280 Pond Street  
Randolph, MA 02368  
Telephone- (781) 681 27 96  
Fax - (781) 963 68 31

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR(S)	DATE	RESIDENCE & PO ADDRESS
Name : <u>KOKEN Marcel</u> Signature : <u>Marcel Koken</u>	Date : Citizen of : The Netherlands	Appartement 116 15 allée Darius Milhaud F-75019 Paris France
Name : <u>QUIGNON Frédérique</u> Signature :	Date : Citizen of : France	6, passage Charles Dallery F-75011 Paris France
Name : <u>DE THE Hugues</u> Signature :	Date : Citizen of : France	146 rue de l'Université F-75007 Paris France
Name : <u>AMEISEN Jean-Claude</u> Signature :	Date : Citizen of : France	35 bis, rue Henri Barbusse F-75005 Paris France
Name : <u>DE BELS Frédéric</u> Signature :	Date : Citizen of : France	c/o M. Bilan 5, rue Frédéric Loliée F-75020 Paris France

15 Résidence de la  
Châtaigneraie  
29170 Pleuven  
FRX

FRX

FRX

FRX